Perrigo Plays To OTC Strength With GoodSense Firm Acquisition
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Geiss, Destin & Dunn's GoodSense brand includes more than 1,500 OTC drugs and nutritional products. The deal could help diminish the impact of earnings headwinds on Perrigo's branded consumer health and Rx generic topicals businesses.
You may also be interested in...
Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot
The firm lowers its 2016 guidance as its European branded OTC drug and nutritional product business and its Rx topicals business appear to be major obstacles to escaping its earnings slump.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.